Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 1 · below the Ichimoku cloud · RSI 43 · MACD below its signal
None of the 29 investors followed here reported a position in PTPI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a PTPI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Walker Wayne RemellDirector | — | 375K | — |
| Jun 4, 2026 | Bernstein Bruce T.Director | — | 1.88M | — |
| Jun 4, 2026 | Boctor FadyPresident | — | 375K | — |
| Jan 1, 2026 | Walker Wayne RemellDirector | — | 500K | — |
| Jan 1, 2026 | Bernstein Bruce T.Director | — | 1.88M | — |
| Jan 1, 2026 | Boctor FadyPresident | — | 500K | — |
| Feb 18, 2025 | Walker Wayne RemellDirector | — | 150K | — |
| Feb 18, 2025 | Bernstein Bruce T.Director | — | 300K | — |
| Feb 18, 2025 | Boctor FadyPresident | — | 450K | — |
| Feb 18, 2025 | Arnold MitchellOfficer | — | 150K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | -12.5 | -14.3 | 16.7 | -14.3 | -16.7 | -40.0 | 33.3 | 75.0 | -57.1 | −62.5% | ||
| 2025 | -28.9 | -65.0 | -29.6 | -82.6 | -88.0 | -5.6 | -11.8 | 0.0 | -20.0 | -20.8 | -36.8 | -33.3 | −99.9% |
| 2024 | -14.2 | 42.1 | -14.0 | -54.3 | -9.2 | -25.4 | -11.4 | -18.0 | 7.2 | 3.6 | -25.9 | 43.8 | −72.1% |
| 2023 | 11.6 | -19.2 | -33.6 | 208.2 | -45.8 | -12.9 | 97.5 | -36.4 | -32.2 | -17.3 | 11.9 | -11.9 | −39.5% |
| 2022 | -48.0 | -20.2 | 13.0 | -27.6 | -13.7 | -13.8 | -5.5 | -17.4 | -22.3 | -5.9 | -14.4 | -43.3 | −93.0% |
| 2021 | -23.6 | -0.9 | 12.0 | -13.7 | -5.9 | 3.3 | -2.9 | -26.0 | -11.1 | -13.0 | 64.4 | 16.4 | −24.3% |
| 2020 | — |
No analyst coverage for this instrument.
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary software as a service (SaaS) platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.
No recent headlines.